CRDL Cardiol Therapeutics
- 2.0800
- -0.1200-5.45%
- 2.0300
- -0.0500-2.40%
Cardiol Therapeutics News
Stocks in Play: Cardiol Therapeutics Inc.
Sector Update: Health Care Stocks Softer Thursday Afternoon
Health care stocks fell Thursday afternoon with the NYSE Health Care Index down 0.5% and the Health Care Select Sector SPDR Fund (XLV) decreasing 0.3%. The iShares Biotechnology ETF (IBB) fell 0.4%. I
Cardiol Therapeutics Shares Fall After Report or Phase II Data for CardiolRx in Recurrent Pericarditis
Cardiol Therapeutics (CRDL) shares were down 16.5% in recent Thursday trading after the company reported eight-week phase 2 clinical data for CardiolRx to treat patients with symptomatic recurrent per
Cardiol Slips After Mid-stage Data for Heart Disease Therapy
Cardiol Therapeutics Releases Phase II Data Showing CardiolRx Reduces Pericarditis Pain and Inflammation | TSX:CRDL, NASDAQ:CRDL
Cardiol Therapeutics Announces Positive Topline Data From Its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Administration of CardiolRx led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx also shown to reduce inflammation in patients with elevated CRP89% of patients have
Express News | HC Wainwright & Co. has reasserted its buy rating on Cardiol Therapeutics (CRDL.US), and has adjusted the target price from $9.00 to $9.00.
H.C. Wainwright Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Maintains Target Price $9
H.C. Wainwright analyst Vernon Bernardino maintains $Cardiol Therapeutics(CRDL.US)$ with a buy rating, and maintains the target price at $9.According to TipRanks data, the analyst has a success rate o
Cardiol Therapeutics Sets Annual Shareholders' Meeting
Analysts' Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics
Cardiol Therapeutics Is Maintained at Buy by Canaccord Genuity
Cardiol Therapeutics Is Maintained at Buy by Canaccord Genuity
Canaccord Genuity Maintains Buy on Cardiol Therapeutics, Raises Price Target to $8
Canaccord Genuity analyst Edward Nash maintains Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and raises the price target from $6 to $8.
CCORF Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Raises Target Price to $8
CCORF analyst Edward Nash maintains $Cardiol Therapeutics(CRDL.US)$ with a buy rating, and adjusts the target price from $6 to $8.According to TipRanks data, the analyst has a success rate of 40.1% an
Cardiol Therapeutics Inc: Canaccord Genuity raises price target from $6 to $8
Cardiol Therapeutics Inc: Canaccord Genuity raises price target from $6 to $8
Express News | Cardiol Therapeutics Inc : Canaccord Genuity Raises Target Price to $8 From $6
Cardiol Therapeutics Reports Q1 Financial Dip
Cardiol Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This growth would be primarily fueled by the expansion of ad
Cardiol Therapeutics Says Phase II ARCHER Trial Presented at World Congress on Acute Heart Failure
Cardiol Therapeutics (CRDLTO) working on treatments for heart disease, on Tuesday said its Phase II trial evaluating the impact of CardiolRx on myocardial recovery in patients with acute myocarditis (
HC Wainwright & Co. : The Cardiol Therapeutics (CRDL.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $9.00.
HC Wainwright & Co. : The Cardiol Therapeutics (CRDL.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $9.00.
Analysis
Price Target
No Data
